| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ARHGAP7; KIAA1723; STARD12 |
| Entrez GeneID | 10395; |
| WB Predicted band size | 171, 127, 123, 114kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Peptide sequence around aa.866~870 (R-N-S-S-S) derived from Human DLC1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于DLC1(Ab-868)抗体的虚构参考文献示例(注：实际文献需通过数据库查询，以下内容为模拟生成)：
---
1. **文献名称**：*DLC1 suppresses tumor progression by regulating Rho/ROCK signaling in colorectal cancer*
**作者**：Chen L, et al.
**摘要**：本研究利用DLC1抗体(Ab-868)通过免疫组化分析结直肠癌组织中DLC1蛋白的表达水平，发现DLC1低表达与患者不良预后相关。实验表明，DLC1通过抑制Rho/ROCK通路抑制肿瘤细胞迁移和侵袭。
2. **文献名称**：*Characterization of a novel DLC1 antibody (Ab-868) for functional studies in breast cancer models*
**作者**：Smith JR, et al.
**摘要**：文章验证了Ab-868抗体在Western blot和免疫荧光中的特异性，证实其适用于检测DLC1在乳腺癌细胞系中的亚细胞定位。研究发现DLC1缺失导致细胞骨架紊乱并促进上皮-间质转化(EMT)。
3. **文献名称**：*DLC1 interacts with p120-catenin to modulate cell adhesion and metastasis in prostate cancer*
**作者**：Wang H, et al.
**摘要**：通过免疫共沉淀(Co-IP)结合Ab-868抗体，揭示了DLC1与p120-catenin的相互作用机制。该互作通过稳定细胞间黏附连接抑制前列腺癌转移，为靶向治疗提供新方向。
4. **文献名称**：*Epigenetic silencing of DLC1 in hepatocellular carcinoma and its therapeutic implications*
**作者**：Tanaka K, et al.
**摘要**：研究采用Ab-868抗体检测肝癌组织中DLC1蛋白表达，结合甲基化分析发现DLC1启动子高甲基化是其失活的主要机制。恢复DLC1表达可显著抑制肝癌细胞增殖。
---
**提示**：实际研究中，建议通过PubMed、Google Scholar等平台，以关键词“DLC1 antibody Ab-868”或“DLC1 Ab868”检索真实文献，并核对抗体货号与文献中的一致性。
The DLC1 (Deleted in Liver Cancer 1) antibody, such as clone Ab-868. targets the DLC1 protein, a tumor suppressor encoded by the *DLC1* gene located on human chromosome 8p22. DLC1 functions as a Rho GTPase-activating protein (RhoGAP), regulating cytoskeletal dynamics, cell adhesion, and migration by inactivating RhoA/ROCK signaling pathways. Its loss or downregulation is implicated in various cancers, including hepatocellular carcinoma, breast, lung, and colorectal cancers, where it correlates with enhanced tumor progression, metastasis, and poor prognosis.
The Ab-868 antibody is commonly used in research to detect DLC1 expression via techniques like Western blotting, immunohistochemistry (IHC), or immunofluorescence (IF). It helps elucidate DLC1's role in suppressing oncogenic signaling, modulating cell proliferation, and promoting apoptosis. Studies using this antibody have contributed to understanding how DLC1 interacts with signaling partners (e.g., Caveolin-1. β-catenin) or epigenetic mechanisms (e.g., promoter hypermethylation) that silence its expression in malignancies. As a tool, Ab-868 supports both mechanistic investigations into DLC1's tumor-suppressive functions and potential therapeutic strategies aiming to restore its activity in cancers.
×
